Shows
Project E | Dein Earnings-PodcastLonza Earnings 2025 | Wachstumssprung, Vacaville-Integration und der Kurs auf 2026In dieser Episode analysieren wir die starken Finanzergebnisse von Lonza, das das Jahr 2025 mit einem Umsatzsprung von 21,7 % auf 6,5 Milliarden CHF und einer erweiterten CORE EBITDA-Marge von 31,6 % abschloss,. Wir beleuchten den Erfolg der „One Lonza“-Strategie sowie den signifikanten Beitrag der neu integrierten Vacaville-Anlage, die maßgeblich zum Wachstum im Bereich Integrated Biologics beitrug und wie der geplante Verkauf der Sparte Capsules & Health Ingredients (CHI) und eine Dividendenerhöhung um 25 % den Weg für den optimistischen Ausblick auf 2026 mit erwartetem zweistelligem Wachstum ebnen.Quelle: https://www.lonza.com/news/2026-01-28-06-30Wie immer gilt: Alle In...
2026-01-2815 min
Investor ExchangeThe Secret To Lonza's Massive FY2025 GrowthExplore Lonza’s successful transformation in this overview of their latest annual results. We discuss the launch of the unified operating model, which has already begun improving customer partnerships and operational execution. The discussion covers the integration of a major facility and how the company is positioning itself for a changing geopolitical landscape.
• Operational Evolution: Learn how a unified team structure is driving efficiency across technology platforms
• Network Integration: Uncover the success of a significant site acquisition and its impact on large-scale production capacities
• Strategic Shifts: Insights into the di...
2026-01-2711 min
Cookaround - Cucina e RicetteFettine di lonza al latteTrovi ingredienti, dosi e passaggi per la ricetta Fettine di lonza al latte qui: https://www.cookaround.com/ricetta/fettine-di-lonza-al-latte.htmlTantissime ricette, con ingredienti, dosi e preparazione sono disponibili sul portale https://www.cookaround.com/
2026-01-1902 min
A view onA View On Innovating Drug Development and ManufacturingInnovating Drug Development and Manufacturing: How External Collaborations Shape the Future of Biotherapeutics
In this episode of A View On, we speak with Andrew Brown, R&D Director at Lonza’s Integrated Biologics, and Zara Asgharpour, Director of External Innovation in Integrated Biologics, about how evolving molecular formats and external innovation are transforming the way biotherapeutics are developed and manufactured.
The world of biotherapeutics is in constant evolution, with new molecular formats, scientific insights, and strategic partnerships shaping the medicines of tomorrow. These increasingly complex biologics require new approaches in development and manufacturing, from developing adv...
2025-12-1517 min
Radio MercatorumOUT.LET - Chi ha paura della frode? Dante e l'enigma della lonza - Prof. Daniele Maria PegorariChe cosa rappresenta davvero la lonza che sbuca nella selva oscura della Divina Commedia? Per secoli si è ripetuto che fosse la lussuria, ma la ricerca filologica ci rivela un’altra verità: la lonza è il simbolo della frode. In questo episodio di Out-Let apriamo una prospettiva nuova sul primo canto dell’Inferno, scoprendo l’ordine nascosto delle tre fiere.
2025-11-1608 min
The PricePlow Podcast#190: One Innovation Labs: LiposoMax® Industry Partnerships Bring True Liposomal Innovation to MarketOn Episode #190 of the PricePlow Podcast, Mike and Ben host a special round-robin format from SupplySide Global 2025, recorded live at the ONE Innovation Labs booth. This episode showcases the collaborative power of the supplement industry, featuring conversations with Dr. Pedro Perez and Anthony Armas (ONE Innovation Labs), Katie Emerson and Karen Todd (Kyowa Hakko), Dan Force (Prinova), Zain Saiyed (Lonza), Dr. Benjamin Weeks (Adelphi University), and Nathan McWherter (Sports Research).
The Miami-based ingredient innovator behind PureWay-C® is ma...
2025-11-121h 05A view onEpisode 8: A View On Process Analytical TechnologiesProcess Analytical Technologies: Real-Time Insight for Smarter Manufacturing
In this episode, we speak with Carrie Mason, Thad Webster, and Ryan McDougall from Lonza’s PAT Center of Excellence about how Process Analytical Technologies are transforming the way biologics are developed and produced.
This episode of A View On takes us inside the manufacturing suite, where data, sensors, and decision-making converge in real time. Our guests explain how process analytical technologies (PAT) bring advanced analytics and spectroscopy directly into bioprocesses, allowing operators and scientists to “see” what’s happening inside a bioreactor without taking samples out.
Tr...
2025-11-1118 min
Beyond Biotech - the podcast from LabiotechNavigating the biotech development journey from first steps to global scale with LonzaLonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from emerging biotechs to top global pharmaceutical companies – to transform therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Founded in 1897 in the Swiss Alps, Lonza has embraced innovation and kept pace with a fast-changing world for more than 125 years. They are a leader in both established and emerging technologies and today their 19,000 employees across more than 30 sites on five continents generate annual sales of more than $4.4 billion. We...
2025-09-0550 minA view onEpisode 7: A View On Spray-Drying mRNA-based TherapiesA View On Spray-Drying mRNA-based Products
Delivering mNRA Therapies: A Bullseye for Asthma and Future Pandemics
In this episode, we speak with Carsten Rudolph, CEO and co-founder of Ethris, about a novel spray-dried mRNA therapy designed to restore immune balance in asthma patients and prepare for future pandemics.
This episode of A View On takes us deep into the lungs, where science, engineering, and medicine converge. Our guest, Carsten Rudolph, CEO and co-founder of Ethris, explains how his team is developing inhalable mRNA-based therapies for chronic respiratory conditions like asthma, rare diseases such as...
2025-07-2823 minInvestor ExchangeLonza Group Half-Year 2025 ResultsLonza's Half-Year Results for 2025 highlight a period of strong financial and operational performance, with an optimistic revised outlook for its core Contract Development and Manufacturing Organisation (CDMO) business. The company is actively implementing a new, streamlined operating model that became effective in April 2025, impacting how its diverse business areas are structured and reported.
• Discover how Lonza's CDMO business showcased impressive growth, leading to an upward revision of its outlook for the remainder of 2025
• Uncover the recovery trajectory of the Capsules & Health Ingredients business, which is progressing as anticipated despite the ongoing preparations for its strat...
2025-07-2216 minA view onEpisode 6: A View On Improving Microbial ManufacturingUnlocking Microbial Manufacturing: Innovation Across the Pipeline
For more than 40 years, microbial fermentation has been the workhorse of biologic manufacturing. From the first recombinant insulin to today’s increasingly complex therapeutic formats, the technology has consistently adapted to meet the needs of patients, developers, and regulators.
Karlheinz Flicker, Director of Microbial R&D, offers a strategic perspective on how microbial systems like E. coli and Pichia pastoris support emerging non-Fc biologics such as nanobodies and cytokines. Later, Joan Cortada, Associate Principal Scientist, walks us through a promising innovation in protein refolding that uses high pressure to...
2025-07-0218 minA view onEpisode 5: A View On Smart Capsule TechnologyA Swallow Instead of a Jab? A Capsule That Delivers Like an Injection
In this episode, we’re joined by Karsten Lindhardt, Founder and CEO of Biograil, to explore how a spring-loaded oral capsule could revolutionize drug delivery—offering patients a needle-free alternative with the same therapeutic impact as subcutaneous injections.
From insulin to monoclonal antibodies, biologic drugs are typically delivered through injections—often multiple times a week. For many patients, this isn’t just painful; it disrupts daily life and can be a major barrier to long-term treatment compliance. Imagine a world where those same treat...
2025-05-2720 min
Short Briefings on Long Term Thinking - Baillie GiffordEuropean growth: unique brands, hidden championsAre European stocks coming back into favour? After years of underperformance, many of the continent’s companies appear undervalued when compared to their historical prices and US counterparts. Investment manager Stephen Paice suggests that a group of growth-focused stocks could be among the biggest winners if sentiment shifts, and he identifies a handful of places they are thriving. Background Stephen Paice is a partner in Baillie Gifford, our Head of European Equities, an investment manager on the Baillie Gifford Growth Trust and European Fund, and a member of our International All Cap...
2025-03-1834 min
Grind 3/29 by Lonza PodcastGrind 3/ 29 Podcast by Lonza ft DC Carson Season 2 Episode 3Grind 3/ 29 Podcast by Lonza ft DC Carson S2 Ep 3This episode of Grind 3/29 with Lonza ....we sit down with Dc Carson and discuss his up and coming project called “Rides and Reels Vol 2. Here we discuss his upbringing, how he started out as a musician and what the future looks like for him as an artist.As a Veteran pilot, we discuss his military career and how his family upbringing has shaped his life. Does DC win the game? Stay tuned in and find ou...
2025-03-041h 04A view onEpisode 4: A View On Developing Acid Reflux TherapyPain in the Gut: Next Generation Therapy for Acid Reflux in the Pipeline
In this episode, we are joined by Kjell Anderson, Chief Scientific Officer at Cinclus Pharma, to discuss a novel treatment for acid reflux.
Millions of people worldwide grapple with acid reflux, which may progress to gastroesophageal reflux disease (GERD). Chronic acid exposure in the esophagus can lead to discomfort, inflammation, and even erosions—tissue damage that can severely affect a patient’s quality of life. While lifestyle modifications and standard proton pump inhibitors (PPIs) offer relief for some, they are not always effe...
2025-03-0421 min
The Witching HourLondon’s Lingering Legend: Jack the RipperFive brutal murders. A city in fear. A killer who was never found. Join us as we analyze one of history’s most infamous unsolved cases, from crime scene details to modern forensic efforts.
2025-02-2121 min
The Drug Discovery World PodcastNano Insights: Unveiling the Role of mRNA Analytics in cGMP Manufacturing with Lonza and beyondIn this podcast we speak to experts from Lonza and Oxford Nanopore about their collaboration to bring direct mRNA sequencing (including N1-Methyl-pseudouridine) to a regulated environment and establish the new gold standard in sequencing technology. We discuss how nanopore sequencing will be used to perform unbiased identity testing while enabling the simultaneous analyses of multiple critical quality attributes such as integrity (mRNA length and poly-A tail length) and capping.
2025-02-2015 min
The Witching HourSilver Screen Screams: Nosferatu (2024) A brand-new segment emerges from the shadows… Silver Screen Screams brings you deep dives into the best horror films, and we’re kicking things off with Nosferatu (2024). Does it deliver the gothic chills we crave? Press play and let’s find out.
2025-02-1340 minThe Witching Hour**February 2025 Podcast Update**A quick podcast update! Thank you all for listening and I am excited for what is to come.
2025-02-0506 minA view onEpisode 3: A View On mRNA EncapsulationDriving Innovation Through Collaboration: The Future of mRNA Therapies
In this episode, we are joined by three experts—Christoph Hein (Fraunhofer IPK), Bernhard Bobusch (FDX Fluid Dynamix), and Sönke Stocker (Lonza)—to explore how advanced fluidics, encapsulation techniques, and a truly collaborative approach are paving the way for potential solid-tumor vaccines now in preclinical trials.
When you think about mRNA-based vaccines, have you ever considered the complex route these microscopic instructions must travel to deliver their life-changing code? This journey, essential for the therapy’s success, lies at the core of pharmaceutical research—where the chall...
2025-01-3023 min
Architektur Basel PodcastBIZ bis Lonza – Schönthal bis KlybeckIst es ein Turm oder doch nicht? Der BIZ-Tower soll durch ein Hochhaus in nächster Nähe ergänzt werden. Das ikonische Lonza-Hochhaus bekommt dereinst gleich zwei neue Nachbargebäude. Die Frage nach dem Hochhaus hat die Basler Architekturwelt auch im Jahr 2024 beschäftigt. Aber nicht nur: beim Bauinspektorat scheint der Wurm drin. Lange Wartezeiten und Personalprobleme verursachen Ärger. Auch im Klybeck liefs nicht rund. Gibt es nun Schadstoffe auf dem Areal oder nicht? Die BVB möchte alle Wartehäuschen ersetzen. Im September wurde allerdings gegen einen Rückbau Einsprache erhoben. Ebenso gegen die Pläne, die Antoniuski...
2025-01-0255 min
OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News“Broadcom knackt 1.000 Milliarden” - Zukunftswette: Nokia & Supplement-Loser: LonzaAktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht’s unbegrenzt per Trading-Flatrate oder regelmäßig per Sparplan. Alle weiteren Infos gibt’s hier: scalable.capital/oaws.Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch.Das Buch zum Podcast? Jetzt lesen.2024 ist das Jahr der unbekannten Billionäre. Broadcom ist jetzt auch einer. Ansonsten beweist die Münchener Rück mal wieder, dass Versicherungen nicht langweilig sind. Abseits davon werden Food-YouTuber und Konzerne für zig Millionen verkauft....
2024-12-1613 min
The Witching HourCreepy Christmas: Part 2 - Naughty or Nightmarish?In Part 2 of Creepy Christmas, Nikki explores the darker side of the holidays with Saint Nicholas, Belsnickel, and Krampus. These figures bring gifts, switches, and terrifying consequences for those who’ve been naughty. Are you ready for the shadows of Christmas?
2024-12-1425 min
The Witching HourCreepy Christmas: Part 1 – The Dark Origins of YuleLong before Christmas as we know it, winter was marked by eerie pagan traditions and ghostly tales. In Part 1 of our Creepy Christmas series, Nikki uncovers the chilling origins of Yule, from the spectral Wild Hunt to the restless spirits said to roam the solstice. Explore the darker side of the season, where firelight battles the long night, and ancient rituals honor both life and death.
2024-12-0532 minA view onEpisode 2: A View On Antibody-Based TherapiesAntibody-Based Therapies: Transforming Modern Medicine
In this episode, we are joined by Ronnie Wei, Head of Biologics Discovery and Development at ModeX Therapeutics, and Atul Mohindra, Head of R&D for Biologics at Lonza, to explore the development and manufacturing of monoclonal, bi-, and multi-specific antibodies and their transformative role in modern medicine.
Everyday life is filled with stories of medical breakthroughs—new cancer treatments, therapies for rare diseases, and vaccines that protect millions. At the heart of many of these advances are antibody-based therapies. These life-changing medicines leverage the natural defense systems of the bo...
2024-12-0426 minThe Witching HourBonus Episode: The Case of Lizzie BordenIn this bonus episode, Nikki dives into the infamous case of Lizzie Borden, dissecting the chilling murders of her father and stepmother. Was Lizzie a cold-blooded killer, an innocent scapegoat, or something in between? Join Nikki as she unravels the clues, the trial, and the enduring mystery that has haunted history for over a century.
2024-11-2320 minThe Witching HourParanoia, Power, and Persecution: The Salem Witch TrialsIn this episode, Nikki unravels the Salem Witch Trials, uncovering the web of accusations, the tragic executions, and the societal tensions that fueled a community’s descent into chaos.
2024-11-2134 minA view onEpisode 1: A View On Emerging Trends in Pharmaceutical Manufacturing, live from CPHI MilanWe are back! Discover the latest in pharmaceutical innovation from CPHI Milan with A View On! This episode explores advancements in bioconjugates, AI-driven drug development, targeted capsule delivery, and new solutions in cell and gene therapy that are transforming patient care. Tune in to hear from Lonza experts on the future of pharma and biotech.
2024-11-0125 minThe Witching HourPumpkins, Costumes, and Spirits: A History of HalloweenHappy Halloween! In the episode, Nikki discusses the origins of some of the most popular traditions of the season.
2024-10-3142 minThe Witching HourBlood, Lust, and Impalement: The History of VampiresIn this episode, Nikki dives into the dark history of vampires. From their origins in ancient folklore to their place in modern pop culture, we explore how these creatures have evolved and why they continue to captivate us.
2024-10-2441 minThe Witching HourBonus Episode: A Word That Won't Die - The CROATOAN MysteryIn this mini episode, Nikki discusses the mystery of CROATOAN - A word found throughout history connected to mysterious deaths and disappearances.
2024-10-2119 minThe Witching HourFear, Folly, and Feminism: The European Witch TrialsFor our first-ever episode, Nikki explores the complicated and disturbing history of the European Witch Trials, and their impact on modern perceptions and pop culture.
2024-10-1745 min
Your Money with Michelle MartinMarket View: Hongkong Land, Lonza, Amazon, Micron, Novo Nordisk, Beyond Meats, Levi's, ValueMax, SingTel, SATSJoin Michelle Martin and Ryan Huang in a tour of markets in minutes! Dive into Hongkong Land's $1 billion revamp of Landmark Mall and its impact on stock performance. Explore the downturn in China's industrial parks affecting companies like Lonza. Discover Amazon's recent stock surge and Micron's mixed earnings report. Get updates on Novo Nordisk, Beyond Meats, and Levi's stock movements. Finally, hear about ValueMax's plans for a Malaysian listing and local market highlights with SingTel and SATS.See omnystudio.com/listener for privacy information.
2024-06-2721 min
TELL me! Der Schweizer Trading PodcastLonza Top-Pick bei den Schweizer Pharma-AuftragsfertigernTELL me! Episode 038 Der Schweizer Trading Podcast von finanzen.ch
Bei dem Schweizer Trading Podcast TELL me! von finanzen.ch, sprechen wir heute über die Aktie Lonza. Für mehr Details, hören Sie doch mal rein.
Lonza, CH0013841017
WICHTIG:
Es handelt sich bei den besprochenen Werten nicht um Anlageempfehlungen. Die hier besprochenen Aktien, ETFs und Hebelprodukte bergen aufgrund hoher Volatilität ein hohes Risiko!
2024-06-2506 minA view onEpisode 11: A View On the History of Capsule ManufacturingTracing the Evolution and Future of Capsule Manufacturing
In this episode, we are joined by Ljiljana Palangetic, Associate Director of Hard Capsules R&D, and Bram Baert, Senior Director of Regulatory Affairs from Lonza, to delve into the intricacies of capsule manufacturing and the evolution of drug delivery technologies.
Your grandmother might have told you to “just swallow your medicine,” suggesting that you may have to endure something unpleasant but necessary. Today, however, this old saying might not ring true, as capsules have become ubiquitous in modern medicine. Favored by 44% of consumers, capsules simplify medication intake...
2024-06-0528 minA view onEpisode 10: Drug Bioavailability EnhancementSimulating the Journey of Oral Medications: A Leap Towards Personalized Medicine
In this episode, we are joined by Deanna Mudie, a senior principal engineer at Lonza, and John DiBella, president of PBPK & Cheminformatics at Simulations Plus, to discuss new techniques in enhancing the bioavailability of drugs.
When you swallow a pill, have you ever pondered the intricate journey it undertakes to deliver its therapeutic effect? This voyage, crucial for the drug's effectiveness, is at the heart of pharmaceutical R&D's quest to enhance bioavailability - the proportion of the drug that enters circulation and reaches th...
2024-03-0530 minA view onEpisode 9: Capsules for Targeted Therapy DeliveryCapsules for Targeted Therapy: A Game-Changer in Modern Medicine
In this episode we are joined by Vincent Jannin, Lonza's R&D Director, to explore Enprotect, the Award-Nominated Capsule Technology.
Imagine starting your day with a simple capsule that goes beyond simply dissolving in your stomach to reach the place in your body where it is needed most before releasing its medicine. That’s just what Lonza’s Enprotect enteric capsules do. They are designed to release medication directly into the small intestine, which represents a significant leap in pharmaceutical delivery. They improve patient compliance without increa...
2024-01-1026 min
Grind 3/29 by Lonza PodcastGrind 3/29 Podcast by Lonza "The Menscast" Episode 10Grind 3/29 Podcast with Lonza Sits down with Danny, Walter, Derek, MAC , and Zay join to discuss, in this monumental one of a a kind podcast : women. We discuss the topic Is chivalry dead? Why is it or why not..What do women expect now a days. Is it the same as when the grandpas did it or the dads for you who had dads?What don’t women get by now that they should have...
2023-12-091h 35
PharmaSource PodcastLonza Capsules and Health Ingredients: The Science of Patient-Friendly CapsulesLonza Capsules and Health Ingredients is the global leader in the capsule manufacturing market, says Julien Lamps, Associate Director of Global Product Management.
Speaking on the PharmaSource podcast, Julien explains how Lonza support the pharmaceutical industry with a range of science-backed capsule innovations.
“We are the most well-known in the market for our Capsugel® brand products” says Julien.
“Our manufacturing footprint is well established. We have 10 manufacturing sites worldwide, in every region of the world, producing 250 billion capsules a year”
This scale means Lon...
2023-11-2414 minA view onEpisode 8: A View On Particle IdentificationEmbark on a microscopic journey into particle identification — the unsung hero of pharmaceutical safety — and uncover how this vital process shields us from unseen threats in every single medication we take.
2023-11-1425 min
Work Life TalentsWork Life Talents - Folge 10 über Lonza und Activision BlizzardIn der zehnten Folge des Podcasts diskutieren Markus und Sandro unter anderem über Lonza und die Akquisition von Activision Blizzard durch Microsoft.
Disclaimer: Die vertretenen Meinungen zu Unternehmen stellen weder eine Anlageempfehlung noch die Meinungen der jeweiligen Arbeitgeber dar.
2023-10-2034 min
Work Life TalentsWork Life Talents - Folge 8 über Sandoz, Lonza und LVMH
In der achten Folge des Podcasts diskutieren Markus, Jann und Sandro über den Börsengang von Sandoz, die aktuelle Situation bei Lonza und die Vorgehensweise von Markus beim Kauf von LVMH.
Disclaimer: Die vertretenen Meinungen zu Unternehmen stellen weder eine Anlageempfehlung noch die Meinungen der jeweiligen Arbeitgeber dar.
2023-10-0638 minA view onEpisode 7: Mid-season wrap-upSeason three so far, we’ve covered a lot!
In this summary episode, A View On host Martina Hestericova shares a secret and goes over a selection of the best ideas from season three so far.
The production team for A View On has managed to keep things moving along smoothly, so you most likely didn’t even notice that Martina was away for four months. She’s back! Listen in as Martina navigates us through a curated selection of the finest moments from the season: from cell culture to highly potent molecules, from inhala...
2023-09-1814 min
Molecule to Market: Inside the outsourcing spaceFrom Powdersize to MicrosizeIn this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with TJ Higley, CEO at Microsize.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with TJ, covering:
The fast, easy, scalable, precise, and non-patent-protected benefits of micronization
How a synergistic capability alliance led to the eventual sale of his business to Lonza Capsugel
The risks and realities of being an entrepreneur acquiring an organization, and then the collective rewards by incentivizing a team
How a ‘getting the band back together’ call led to TJ tak...
2023-09-1549 min
Svet na dlani19 – ŠVICA / Živa Vučkovič: “Skrivnostna sestavina na poti do Nobelove nagrade je čokolada”Ste vedeli, da države, kjer pojedo več čokolade, dobijo več Nobelovih nagrad? Ker je znanstveno potrjeno, da čokolada pozitivno vpliva na kognitivne sposobnosti, se zdi verjetno, da prav uživanje čokolade ustvarja ugodno okolje za razvoj bodočih Nobelovih nagrajencev!
V tokratni epizodi sva z Mariem skočila med visoke vrhove Alp, kjer sva se pogovarjala z Živo Vučković, strukturno biologinjo. Živa je delila svoje izkušnje iz obdobja, ko je zaključila svojo diplomo in doktorat, pa vse do dela v podjetju Lonza. Pogovarjali smo se o njeni poti na drugo stran sveta, v Avstralijo, in...
2023-09-041h 04
SciKonnect PodcastS4 EP 11 | Transition from PhD to Industry | Process Development | Scientist | Lonza | USA | Sreyashree BoseSreyashree (Sreya) Bose, PhD is a process development scientist at
Lonza, USA. She completed her Bachelor's degree in Biotechnology in
India, and then went on to earn her PhD at Texas A&M University,
where she studied Telomere biology in plants. She did a short postdoc in
a breast cancer lab before joining Lonza. The interview process at
Lonza included an online application, referral from a current employee,
an initial HR screen, an interview with the hiring manager, and a panel
interview with multiple people. Sreya's role as a process development
scientist at Lonza's cell and gene therapy business...
2023-08-2222 minA view onEpisode 6: A View On CAR-T TherapiesCAR-T Cell Therapy: Re-engineering the Immune System in the Fight Against Cancer
In this episode, Tamara Laskowski, Senior Director of Clinical Development in Personalized Medicine at Lonza, and Aya Jakobovits, from Adicet Bio, discuss the therapeutic potential of CAR-T cell therapy.
CAR-T cell therapy has generated immense enthusiasm within the oncology community since its first FDA approval in 2017. Currently, there are six commercially approved CAR-T cell-based therapies, with more on the horizon. These therapies have exhibited remarkable efficacy, particularly for patients who have exhausted standard treatment options. Industry experts Tamara Laskowski and Aya Jakobovits attest to...
2023-07-3124 minMolecule to Market: Inside the outsourcing spaceWheeler CDMO Avengers...assemble!In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jesse McCool, Co-Founder and CEO at Wheeler Bio.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jesse, covering:
His journey from the Lonza bench to the boardroom as CEO of Cytovance CEO before becoming a founder
Building a CDMO from a blank canvas via a pit stop of C19 testing
What makes Oklahoma City an attractive place to do business with its mixed blend of life science, tech and biomanufacturing expertise
Ho...
2023-06-2340 minA view onEpisode 5: A View On Highly-Potent APIsLonza experts Selene Araya and Charles Johnson discuss the manufacturing process, trends, and future of highly potent compounds (HPAPIs). They highlight Lonza's facilities and expertise in producing HPAPIs across various technologies and scales, ensuring advanced containment and addressing bioavailability challenges.
2023-06-0520 min
EMEA Recruitment PodcastEMEA Recruitment Podcast #158 - Making a Meaningful Difference - Madlaina Brogt & Sally HighamWe were honoured to welcome Madlaina Brogt, Regional Head & Recruitment Delivery, and Sally Higham, Director – Head of Talent Attraction, at Lonza, onto the EMEA Recruitment podcast. “To see that people with a joint goal can make the impossible possible is an experience I will never forget.” Speaking to Paul Toms from the Lonza Tower in Basel, Madlaina reveals that the last thing to make her smile was the local Swiss chocolates she received from Lonza to celebrate its 125th anniversary. For Sally, her son always brings a smile to her face; she finds it nice to step...
2023-05-0859 min
GeldmeisterinInvestieren in Healthcare: Pharma alleine ist zu wenigDemographie, technischer Fortschritt und Konjunktur-Resistenz als Treibe für Healthcare-Aktien
Man muss sein seine Gesundheits-Investment breit aufstellen, nur Pharma wäre zu riskant, meint Andreas Scharf, Chef-Analyst Healtcare bei Apo Asset Management. Er teil diesen Sektor in vier großen Subsektoren: Die Medizintechnik, die Krankenversicher und Dienstleister, Biotech und Pharma. Treiber der Gesundheitsaktien sei die Demographie, der technologische Fortschritt und die Unabhängigkeit des Gesundheitssektors von der Konjunktur. Dass man die Pharmaindustrie zurück nach Europa bringt sieht er als Chance, allerdings gibt es von der Kostenseite Wettbewerbsnachteile, weil es die nachhaltigere Produktion in Europa nicht zum Nullt...
2023-04-2332 minA view onEpisode 4: A View On Medical DevicesIan Thomson from Ypsomed and Roman Mathias from Lonza discuss the market trends in injectable delivery devices, their manufacturing process, and their future in sustainable pharma. Injectable devices offer various benefits, including improved convenience, accuracy, and safety, allowing for precise dosing while reducing the need for hospital visits.
2023-04-1126 minA view onEpisode 3: A View On Manufacturing Cell and Gene TherapiesScaling Up Cell and Gene Therapies: Automation Is the Next Step
In this episode, we take a deep dive into manufacturing cell and gene therapies with Lonza expert Behnam Ahmadian Baghbaderani, executive director of Cell and Gene Therapy Process Development.
Cell and gene therapies have the potential to revolutionize the treatment of rare genetic diseases, cancer, and neurodegenerative disorders. These therapies involve extracting cells or genetic material from a patient or donor, altering them and then re-injecting them back into the patient to provide a highly personalized treatment. However, the manufacturing process for these therapies is...
2023-02-2123 min
The bluEPrint by Executive PlatformsPartnering Together to Build the Future of Cell and Gene Therapy — A Conversation with Dr. Behnam Ahmadian Baghbaderani of LonzaAt the 2022 edition of the Biomanufacturing World Summit series held November 13th to 15th in San Diego, we spoke with Dr. Behnam Ahmadian Baghbaderani, Lonza's Global Head of Process Development, Cell & Gene Technologies, about where the industry is now on Cell and Gene Therapy commercialization, where it wants to be in the next few years, and how biopharmaceutical manufacturers are building the capacities, capabilities, and connections necessary to bridge the gap between today and tomorrow. When is the right time to partner with other organizations? How can the industry work to keep costs down, making these amazing new treatments...
2023-01-1925 min
AI StoriesGreg Coquillo - Technology Manager at Amazon #26Our guest today is Greg Coquillo, Technology Manager at Amazon and startup investor. Greg is also a LinkedIn Top Voice in Technology & Innovation (2021) and Data Science & AI (2020).In our conversation, Greg first explains how he got into the field and why he is so excited about working in the AI space. He also shares his view on Data Science and the skills required to become a great Data Scientist. We then dig into his career focusing on Lonza and Amazon. Greg talks about a price optimisation model he built to increase Lonza’s profit margin by...
2023-01-191h 07
2023-01-1338 minA view onEpisode 2: A View On Manufacturing Inhaled Drug ProductsWhat If the Jab Were a Puff? A Look at Drug Delivery to the Lungs
In this episode we explore the advantages of using inhalers for drug delivery with Lonza experts Kim Shepard and Matt Ferguson.
In late 2022, China introduced the world’s first Covid-19 vaccine to be inhaled into the lungs. The Chinese scientists who developed the vaccine tout its ability to directly stimulate the immune system’s first line of defense – the lungs’ mucous membrane. However, vaccines are just the tip of the inhaler iceberg. While we all are familiar with metered-dose inhalers, as well...
2023-01-1022 minA view on*REPOST* Horseshoe crabs and recombinant factor CSafe Jabs Thanks to Horseshoe Crabs: Making Sure Your Injection is Free of Endotoxins
Allen Burgenson, Lonza’s expert for all things testing, speaks to us about the dangers of endotoxin contamination and the future of non-animal testing for it.
“Before testing for endotoxins in the 1940s, a physician literally had to gauge the risk to your life because of something called injection fever,” explains Allen Burgenson. Luckily, we’ve come a long way since then. Thanks to advanced testing methods, one can rest assured today that any sort of injection or implant is completely free of dangerou...
2022-12-2118 min
In Good Company with Nicolai TangenAlbert Baehny Chairman of Lonza and GeberitIn this episode, Nicolai Tangen talks to Albert Baehny, the Chairman of Lonza and Geberit. Albert was the first person Nicolai called for advice when he became CEO of the fund. Check out what his advice was and much more!The production team on this episode were PLAN-B’s Martin Oftedal and Olav Haraldsen Roen. Background research were done by Sigurd Brekke with additional input from our portfolio manager Emily Heaven, Justin Morris and Martin Prozesky. Links:Watch the episode on YouTube: Norges Bank Investment Management - YouTubeWant to learn more about the...
2022-12-0730 minA view onEpisode 1: A View On Cell Culture MediaDeveloping Cell Culture Media For Growing Cells
We are back! And in the first episode of our new season, we explore growing cells for therapeutic purposes with Lonza specialists Alexis Bossie, Director of Media R&D, and Tariq Haq, Senior Director of Global Media Marketing.
Lab-grown meat is having a moment—the FDA just declared one company’s cultivated chicken safe to eat, and another type of lab poultry was just served for dinner to delegates at this year’s COP27 climate conference in Egypt. Whether this piques your pallet’s curiosity or turns your stomach, one th...
2022-11-3027 minA view onEpisode 11: Season 2 HighlightsJoin us in celebrating the finale of our second season of A View On, the Lonza podcast.
Over the past few months, we have brought you a series of insider conversations with our experts at Lonza, our partners, and leaders in the industry exploring the new pharma and biotechnology trends. We explored exciting topics, such as oncolytic viruses, the human microbiome, antibody-drug conjugates, nuances of early drug development, capsule manufacturing, and the use of artificial intelligence in the pharma industry.
In the latest episode, the podcast host, Lonza’s Martina Ribar Hestericová, recaps the highlights fro...
2022-10-3113 minA view onEpisode 10: AI in the Pharma IndustryArtificial Intelligence and Life Sciences: The Dawning of a Digital Revolution in Pharma Manufacturing
Dr. Loubna Bouarfa, CEO of OKRA.ai, and Stephan Rosenberger, Lonza's Head of Digital Transformation, discuss how AI is currently transforming the pharma industry.
Machine learning is an essential subset of the vast field of Artificial Intelligence, in which computer programs aim to mimic human intelligence. Machine learning is at work in many of the algorithms that impact our daily lives, from suggesting new songs we might like to targeting ads. These algorithms learn from large data sets similarly to how...
2022-08-3126 minA view onEpisode 9: De-risking Drug DevelopmentWhere There’s A Risk, There’s A Way: De-risking Drug Development at the Earliest Stages
Lonza’s wide array of analytical tools and professional experience create a go-to solution for small biotechs looking to decrease risk in their drug development process.
An evolving toolbox of technology and advanced scientific knowledge is fueling the growth of a wide range of next-generation drugs in today’s pipelines. These novel but complex products, while offering the ability to treat previously unmet medical needs across the globe, also present many challenges. This is often due to their unique profiles...
2022-07-3125 minMolecule to Market: Inside the outsourcing spaceThe global pharma leader with an eye on societal impactIn this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Enloe, President and CEO at Societal™ CDMO. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:
Being at the birth of viral vectors and the-infant gene therapy field in the 90s... but choosing not to be there today.
After a career spent all over the world - he shares his pearls of wisdom of what he’s learnt from a lifetime of international business.
Navigating business confusion and redefining companies from the ins...
2022-06-2051 minA view onEpisode 8: Colors of CapsulesCapsule Manufacturing: It’s Not Only What’s Inside That Counts
The recent EU ban on Titanium Dioxide and changing customer habits are shaking up capsule production.
Over the past few years, the coloring and manufacturing of pill capsules have undergone significant changes due to new EU regulations and customer demand for natural ingredients. And while originally invented to mask and protect the contents inside a capsule, research suggests that the color of a tablet or pill can affect how patients feel about their medication.
Until recently, manufacturers have primarily used Titanium Dioxide (TiO2...
2022-06-2024 min
Grind 3/29 by Lonza PodcastGrind 3/29 Podcast by Lonza Ep. 1 w/ Maesixx GrahmGrind 3/29 Podcast by Lonza Ep. 1. w/ Maesixx GrahmCheck out his website https://soo100.comToday we discuss the secret to success as an entrepreneur. Lessons learned in the music industry.. Music production from a creators stand point and legacy. Midiots and the soo100 brand expansions. How we want to help the community.Find all social media for Lonza (Zay). @beatsbylonzaSupport the show
2022-06-0949 minA view onEpisode 7: Antibody-Drug ConjugatesAntibody-drug Conjugates: Next-Generation of Targeted Cancer Treatments
Iwan Bertholjotti and Laurence Bonnafoux from Lonza give an insider look at how these promising treatments make it from development to commercialization.
Chemotherapy is the first-line treatment for most types of cancer. However, one of the major challenges with this approach is that it targets both cancer and healthy cells, with patients suffering severe side effects. A new class of therapies, called antibody-drug conjugates, or ADCs, can target tumors much more precisely by harnessing the power of antibodies. The antibody can bind specific types of tumor cells, delivering...
2022-05-0219 min
Informed ConsentHep B and Vitamin K (Vaccine Conversation Series Pt 6)On the day our newborn children our born, they are jabbed with not one, but TWO injections. Not even before they have lived Earth side 24 hours are they already given shots.This week, I cover the two shots that are administered at birth, the Hepatitis B and the Vitamin K shots. I cover lots of important discussions as well as ask some pretty serious questions.Should we REALLY be injecting our babies on the day they are born? Subscribe and hang out with me every Wednesday to stay u...
2022-04-201h 04
Insights Xchange: Conversations Shaping Academic ResearchScience as a Way of Life with Martina Ribar HestericováIn the second part of the conversation with Martina Ribar Hestericová, hosts Nikesh Gosalia and Jayashree Rajagopalan dive deeper into the world of science communication by exploring concepts such as inclusivity in science communication and English as the global language of science. Martina talks about her ideas for nurturing a love for science among young people by using appealing and age-appropriate language, starting early in elementary school, and teaching science as a way of life rather than an academic subject. The discussion covers tips for running a successful science-based account on Instagram, Martina’s transition from academia into science jou...
2022-04-0422 minInsights Xchange: Conversations Shaping Academic ResearchScience Communication and the Post-Pandemic Future with Martina Ribar HestericováJoin Nikesh Gosalia and co-host Jayashree Rajagopalan in this conversation with science communicator Martina Ribar Hestericová. As the creator of the popular Instagram account science_exercises.eu, Martina is on a mission to make science more accessible to everyone. Martina talks about giving back to society by communicating science, interacting with young scientists from other parts of the world, and bringing science communication into the mainstream. She shares a personal anecdote on how a frustrating lab session on a late Friday evening led to the creation of science_exercises.eu and made her realize the impact of eye-catching visuals. M...
2022-03-2824 minA view onEpisode 6: Manufacturing of ExosomesPutting Manufacturing First: Codiak Moves Swiftly into Clinical Trials with Exosome-based Treatments
Sriram Sathyanarayanan, Codiak’s CSO, and Linda Bain, their CFO, share how the company moved into clinical trials in under 6 years.
Exosomes, extremely small vesicles shed by all cell types, promise to become a viable delivery system for treatments of many diseases. But until recently, manufacturing them at a commercially viable scale has been unfeasible. That is why in 2015 the company Codiak took a two-pronged approach to developing exosome-based treatments: prioritizing both the engineering and manufacturing tracks from the outset. A mere...
2022-03-1422 minA view on*Repost* ExosomesIn this reposted episode from December 2020, we're exploring how a better understanding of exosomes is leading to new treatments and diagnostic technologies with Uwe Gottschalk.
According to Uwe, the exosome revolution is already in full march. As researchers begin to identify how these cell-generated, nano-sized delivery drones function in the human body, novel drug delivery prospects are emerging, including applications for cancer, neurodegenerative diseases and spinal cord injury recovery. Perhaps even more exciting is the role exosomes will play in diagnostic applications in the near future, wherein a liquid biopsy, based on a blood sample, would detect c...
2022-03-0912 min
Food Matters Live PodcastWhat role can probiotics play in sport performance?What role can probiotics play in helping all of us, whether we're casual runners or elite athletes, achieve our fitness goals?The link between diet and sports performance is a fascinating area. At its heart is the gut microbiome - that colony of microbes that digests our food and regulates our metabolism - it can also affect our behaviour, our emotions, and our overall health.In this episode of the Table Talk podcast, in partnership with Lonza, Stefan Gates asks: What is the relationship between the gut microbiome and sports performance?And w...
2022-03-0126 minMolecule to Market: Inside the outsourcing spaceFrom corporate rebel to CDMO entrepreneur
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hanns-Christian Mahler CEO at ten23 health.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hanns, covering:
Transitioning from the structure and scale of Merck, Roche and Lonza into an entrepreneurial start-up CDMO leader.
Having a business purpose focused on the triple-bottom line that is not just profit - patients, people and planet.
Tips and insights of how a CDMO can play its part in encouraging su...
2022-02-2550 minA view onEpisode 5: Importance of ImmunogenicityDe-risking Drug Development: Early Testing for Toxicity Saves Time and Resources
Yvette Stallwood, head of Lonza’s Early Development Services, talks about patient safety and other advantages of early testing for immunogenicity in the drug development pipeline.
In the high-stakes drug discovery game, from IND filings all the way up through the clinical trial phase, regulatory authorities are now expecting developers to have an immunogenicity risk strategy in place. “It really is essential that drug developers assess the immunogenicity risk as early as possible in the pipeline, as not only can it impact the fu...
2021-12-2018 minA view onEpisode 4: MicrobiomeHost and Health: Tailoring Personalized Medicine Using The Unique Microbiome Fingerprint
Professor Eran Elinav from the Weizmann Institute of Science discusses how the interaction between the microbiome and its host is transforming personalized medicine.
“I believe that in the next five to ten years, exploiting the potential of the microbiome will be central to personalized and precision medicine,” explains Eran Elinav. His research into this second genome in the human body at the Weizmann Institute of Science in Isreal is shedding light on how these trillions of cells function and interact with their host...
2021-11-2506 minA view onEpisode 3: Antibody Biopolymer Conjugates for OphthalmologyBridging Business and Biotechnology: Kodiak Sciences Is Increasing Treatment Efficacy for Retinal Diseases
Victor Perlroth, MD, the Chairman and CEO of Kodiak Sciences, discusses how the company’s ABC platform medicines are designed to treat the leading causes of blindness.
Age-related macular degeneration (AMD) is one of the leading causes of blindness in adults worldwide. This disease deteriorates the macula, a miraculous little spot on your retina that allows for precise vision in good light. Although several treatments exist for macular deterioration, they require frequent trips to the doctor’s office for uncomfortable but q...
2021-10-2024 min
VOGLERCAST#45 VoglerCast: Colágeno UC-II em alimentos e bebidasMarina Rodrigues (Lonza) e Diana Lima (Vogler) são as convidadas da semana, para anúncio da parceria entre Lonza e Vogler na distribuição de colágeno tipo II para o mercado de alimentos e bebidas.
2021-09-2714 minA view onEpisode 2: Horseshoe crabs and recombinant factor CSafe Jabs Thanks to Horseshoe Crabs: Making Sure Your Injection is Free of Endotoxins
Allen Burgenson, Lonza’s expert for all things testing, speaks to us about the dangers of endotoxin contamination and the future of non-animal testing for it.
“Before testing for endotoxins in the 1940s, a physician literally had to gauge the risk to your life because of something called injection fever,” explains Allen Burgenson. Luckily, we’ve come a long way since then. Thanks to advanced testing methods, one can rest assured today that any sort of injection or implant is comple...
2021-09-0618 min
The Qualitalks PodcastWhat are CMOs and what are they good for (Part 1) [Kurt In Albon from Lonza]In this podcast, we talk about CMOs and CDMOs, i.e., Contract Manufacturing Organizations.
What they are, how they work, their past and expected future, and everything you need to know about them as a startup, a company, or just as an individual.
Our highly experienced and knowledgeable guest for this session is Kurt in Albon.
Kurt is Global Head of Information Quality at Lonza, one of the biggest CMOs in the world. He has been in the pharmaceutical industry for more than 25 years and holds leading-edge expertise in data integrity, pharmaceutical validation, i...
2021-08-2540 min
The Qualitalks PodcastLeadership Lessons From the Head of Global Information Quality at LonzaIn this podcast with Kurt In Albon, we will look at the concept of true leadership and its importance in the pharmaceutical industry. Kurt will tell us what essential qualities are required to be a successful leader, what pharma companies should look for when hiring talent, and some valuable tips for people who aspire leadership.
Who is Kurt In Albon?
Kurt is Global Head of Information Quality at Lonza, one of the biggest CMOs in the world. He has been in the pharmaceutical industry for over 25 years and holds leading-edge expertise in data integrity, pharmaceutical...
2021-08-1843 min
A view onEpisode 1: Oncolytic virusesA Welcome Virus: Cracking the Viral Code for the Battle Against Cancer
Chairman and founder of PsiVac, Prof. Ghassan Alusi, and the chief operating officer, Imad Mardini, discuss how the company’s proprietary oncolytic virus platform offers new hope for cancer patients.
During a time when everyone actively fears viruses (especially THE virus) and their mutations, it is only cancer cells that have cause to worry about oncolytic viruses, and rightly so. These mutated viruses are administered directly into a tumor. Once inside, they crack open the tumor’s cells in a process known as lysi...
2021-08-0219 min
ECOLonza-ImpfstoffproduktionDie ETH Zürich schickt Studierende als temporäre Arbeitskräfte nach Visp. Zudem: Die Schweizer Firma Puregene wertet mit künstlicher Intelligenz das Erbgut von Cannabis aus – ein Durchbruch in der Pflanzenzucht? Und: Hans-Peter Pleischs Debakel mit seinem Skigebiet-Projekt in Kirgistan.
Dringend gesucht: Neues Lonza-Personal
Der Pharmakonzern braucht für den Ausbau seiner Covid-Impfstoffproduktion dringend mehr Personal. Jetzt gibt es eine erste Entlastung: Die Chemie-Ingenieur-Abteilung der ETH Zürich entsendet Studierende zur temporären Unterstützung nach Visp. Dass dies so rasch gelungen ist, war aber alles andere als selbstverständlich. Die «ECO»-Reportage.
Cannabis – DNA-Entschlüsselung mit künstlicher Intelli...
2021-06-0729 minECOLonza-ImpfstoffproduktionDie ETH Zürich schickt Studierende als temporäre Arbeitskräfte nach Visp. Zudem: Die Schweizer Firma Puregene wertet mit künstlicher Intelligenz das Erbgut von Cannabis aus – ein Durchbruch in der Pflanzenzucht? Und: Hans-Peter Pleischs Debakel mit seinem Skigebiet-Projekt in Kirgistan.
Dringend gesucht: Neues Lonza-Personal
Der Pharmakonzern braucht für den Ausbau seiner Covid-Impfstoffproduktion dringend mehr Personal. Jetzt gibt es eine erste Entlastung: Die Chemie-Ingenieur-Abteilung der ETH Zürich entsendet Studierende zur temporären Unterstützung nach Visp. Dass dies so rasch gelungen ist, war aber alles andere als selbstverständlich. Die «ECO»-Reportage.
Cannabis – DNA-Entschlüsselung mit künstlicher Intelli...
2021-06-0729 min
科科咖啡館20210602 EP7 國際疫苗及經濟狀況追蹤贊助科科人一杯咖啡 https://pay.firstory.me/user/ckfzpluecnopd0800l0z70bv3經濟學人每日濃縮逐字稿：https://www.economist.com/espressoThe World Health Organisation approved Sinovac Biotech’s covid-19 vaccine for emergency use. It recommends that CoronaVac, the Chinese-produced vaccine, be given to people aged 18 and over, with a second dose two to four weeks later. Over 430m doses of the vaccine have already been administered. WHO approval will allow it to be included in COVAX, the global vaccine-sharing scheme.Joe Biden visited Tulsa, Oklahoma, where hundreds of African-Americans were massacred by a white mob in 1921. At least 35 blocks of black-owned buildings—houses, businesses, a hospita...
2021-06-0228 minA view onEpisode 11: Season 1 recapIt’s the season finale for A View On, the Lonza podcast. Over the past 12 months of our initial run, we have brought you a series of conversations exploring the new pharma and biotechnology trends. We spoke to Lonza and the industry experts and discussed exciting topics, such as exosomes, stem cells, drug product testing, bioprinting, and much more.
In the latest episode, the podcast host, Lonza’s Martina Ribar Hestericová, recaps the highlights from this season and looks forward to later this year for what is coming up in the next season.
Interested to learn...
2021-05-2107 min
European Pharmaceutical Review podcastEPR Podcast Episode 2 – Bioavailability enhancement with Dr Deanna Mudie, LonzaIn European Pharmaceutical Review’s latest podcast episode, supported by Lonza, Assistant Editor Hannah Balfour discusses all things bioavailability with Dr Deanna Mudie, a Principal Scientist in Research and Development at Lonza’s site in Bend, Oregon, US.
“For oral drugs, bioavailability is the fraction of the administered dose that actually reaches your systemic circulation unchanged,” explains Deanna, continuing that it must be high to ensure all or most of the drug can reach its site of action for the best therapeutic effect. She went on to explain how dissolution and solubility both factor into how much drug rea...
2021-05-1117 minA view onEpisode10: Phage TherapyDevouring Bacteria: How Phage Therapy Is Shaping Antibacterial Treatments of the Future
In this episode we speak with the CEO of BiomX, Jonathan Solomon, about producing and using phages to test and treat various diseases and conditions.
Until very recently, treating a condition such as acne with an army of microscopic bacteria-destroyers known as phages—bacterial viruses that target and kill specific bacteria—would have seemed highly unlikely. However new research linking acne to an imbalance in the skin’s microbiome has opened the door to innovative treatment approaches. That’s where the biotech company BiomX com...
2021-03-3006 minA view onEpisode 9: Streamlining the cell and gene therapy manufacturingDelivering Personalized Therapies: Streamlining the Supply Chain for a New Generation of Treatments
In this episode, we speak with Amy DuRoss, Co-Founder and Chief Executive Officer of Vineti, about the challenges facing "just-in-time" manufacturing and delivery of personalized therapies—and the solutions her digital startup provides.
According to Amy DuRoss, the COVID-19 vaccine distribution has exposed existing deficiencies in the entire pharmaceutical supply chain. This situation echoes, albeit on a far smaller scale, the distribution complexities of delivering cell and gene therapies (CGT). Unlike more traditional treatments, CGT requires the extraction of live cel...
2021-02-2416 minA view onEpisode 8: ExosomesExosomes Know Where To Go: Using the Body's Own Cell-to-Cell Communication Network for Diagnostics and Drug Delivery
We speak with Uwe Gottschalk, the Chief Scientific Officer of Lonza, about how a better understanding of exosomes is leading to new treatments and diagnostic technologies.
According to Uwe Gottschalk, the exosome revolution is already in full march. As researchers begin to identify how these cell-generated, nano-sized delivery drones function in the human body, novel drug delivery prospects are emerging, including applications for cancer, neurodegenerative diseases and spinal cord injury recovery. Perhaps even more exciting is t...
2020-12-1612 minA view onEpisode 7: MicrobiomeBugs as Drugs: Harnessing the Therapeutic Potential of the Microbiome
Lukas Schüpbach, the CEO of Bacthera, and Gemma Henderson, Bacthera’s Head of Project and Portfolio Management, speak to Lonza about creating pharmaceuticals from the human microbiome.
The human microbiome, comprised of trillions of bacteria, fungi, viruses, and archaea, is unique to each individual and develops over the course of lifetime, stabilizing once we reach adulthood. Despite the widespread understanding that this microbiome is a key component to our health, there are currently no commercially available live biotherapeutic products (LBPs). There is, howe...
2020-11-2508 minA view onEpisode 6: Gene editingSince the arrival of Crispr in 2009, gene editing has made its way into labs. Its groundbreaking importance was acknowledged through the 2020 Nobel Prize in Chemistry. Expanding gene editing for medical treatments, Cellectis focuses its 20 years of experience on developing cancer immunotherapies.
Curious to Know More?
Cellectis CEO André Choulika explains the technology of allogenic gene editing they invented in this episode of the podcast "A View On."
2020-10-1510 minA view onEpisode 5: Therapy administration and its safetyIn 2016 Lonza established its Drug Product Services (DPS) to realize this supply chain model for its partners and clients. Since then the DPS has grown to a workforce of over 250 experienced experts focused on safety, efficacy and quality. To ensure that Lonza’s pharmaceuticals perform as expected in real-world situations, the DPS team simulates the entire administration process until certain the patient will receive the correct dose of the highest quality.
2020-09-2110 minMolecule to Market: Inside the outsourcing spaceOld world solutions won’t work for new world problemsIn this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sara Lesina, Global Marketing Director of Pharma & Nutrition, Capsules and Health Ingredients at Lonza. A multilingual, international marketing leader, Sara oversees the global marketing and product line management team for the capsule business of Lonza, Capsugel®.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Sara Lesina, covering how diversity in her life and career has given her a much more open, flexible and balanced view of the world and how it has hel...
2020-09-0140 minA view onEpisode 4: Cannabinoid scienceCannabinoids are emerging as a treatment option for autoimmune and other immune-related diseases thanks to their modifications as synthetic derivatives. Emerald Health Pharmaceuticals has widened the potential application of cannabinoids by designing cannabidiol and cannabigerol derivatives that have a greater effect on the endocannabinoid system and can interact with receptors and pathways from other biosystems. Alain Rolland, COO of EHP, talks about using cannabinoids for unmet medical needs.
2020-08-2008 min
Círculo ViciosoCírculo Vicioso #015 - Lonza (Creador de SoyLonza y dueño de bar de vinos DOC)Vino vs. Cerveza, Bares, Comida, TikTok vs. Instagram vs. YouTube, Interés en cosas cotidianas, Reivindicación del postre de vainilla, Tinelli vs. Pergolini, Responsabilidad Spiderman, Restaurante de Puré, Videojuegos de antes, Alejo y Valentina, Locoarts, Mono Mario, El bananero, Marito Baracus
Seguinos en Twitter:
Pablo Wasserman: @pablowasserman
Juan Ruocco: @realjuanruocco
Círculo Vicioso @circulovicioso8
(0:00) Intro
(1:01) Comienzo
(2:15) ¿Hay competencia de MercadoPago? Caso OLX y Marketplace
(5:55) TikTok vs. Instagram vs. YouTube
(11:20) ¿Quien es Lonza? Vino vs. Cervez...
2020-08-143h 13A view onEpisode 3: Mesenchymal stem cells for COVID-19 treatmentMesoblast CEO Dr. Silviu Itescu speaks to Lonza about the company’s advanced portfolio of anti-inflammatory allogeneic cellular medicines including remestemcel-L, which is currently being evaluated in a U.S. Phase 3 randomized controlled trial for acute respiratory distress syndrome (ARDS), the principal cause of mortality due to COVID-19 infection.
2020-07-1909 minA view onEpisode 2: Cell-penetrating peptides for cancer treatmentOne of the limitations of cancer therapy is off-target activity, which often has devastating effects on patients’ life quality. A novel strategy pursued by Cybrexa Therapeutics uses treatments specifically targeting solid tumors by taking advantage of one of their universal biomarkers – acidity. By using cell-penetrating peptides bearing an anticancer cargo load, their platform brings the treatment directly inside tumors, leaving healthy cells alone and minimizing bystander killings.
2020-06-2808 minA view onEpisode 1: BioprintingScientists have been printing cells for decades, but with the arrival of 3D bioprinters, getting printed tissue models to behave like living tissue has proved elusive. That is why angiogenesis and vascularization are two holy grails of 3D bioprinting. Allevi is not stopping at Earth-bound breakthroughs. The US company has also secured funding for simultaneous bioprinting experiments on the International Space Station.
2020-06-2208 min
PCS to Corporate AmericaCameron-Brooks Podcast: Episode 62 – From Aviation To Biotech Contract ManufacturingWelcome back! On this episode, I interview Melanie Mansbach, a JMO who transitioned to the biotech contract manufacturing industry. She is a former Army Aviation officer who transitioned to Lonza in 2016. She is managing a technical team of people who essentially produce very technical and intricate pharmaceutical products. Lonza a 120 year old Swiss company. They are a contract manufacturer for the biggest pharmaceutical companies in the world.
For the first half of the podcast, Melanie gives an in-depth description of
what biotech contract manufacturing is and what she does in her Manager role...
2018-11-0544 min